Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

HDM1702

Stage Phase 3Stale

Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co

Route injection

Sources

registry, as of 2025-06-25Stale

https://clinicaltrials.gov/study/NCT07036172

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 460. Conditions Obesity Control. This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental

ClinicalTrials.gov NCT07036172 protocol and results modules

Studies

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Registry NCT07036172

Phase Phase 3

Status Recruiting

Enrollment 460

Start 2025-01-03

HDM1702

Regimen once weekly

Weeks 16

Population Obesity Control

WEGOVY®

Regimen once weekly

Weeks 16

Population Obesity Control